Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Price Target Increased to $25.00 by Analysts at Alliance Global Partners

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) had its price target hoisted by Alliance Global Partners from $20.00 to $25.00 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Alliance Global Partners’ price objective would suggest a potential upside of 266.57% from the company’s previous close.

A number of other research analysts have also recently weighed in on ATNM. HC Wainwright dropped their price objective on shares of Actinium Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, August 3rd. Zacks Investment Research downgraded shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 16th.

Actinium Pharmaceuticals stock traded up $1.06 during midday trading on Wednesday, hitting $6.82. 24,723 shares of the stock were exchanged, compared to its average volume of 261,670. Actinium Pharmaceuticals has a fifty-two week low of $5.70 and a fifty-two week high of $13.18. The firm has a market cap of $145.48 million, a PE ratio of -3.73 and a beta of 1.03. The stock’s 50-day moving average price is $10.46.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings results on Friday, July 30th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.05. The company had revenue of $0.27 million for the quarter. On average, analysts expect that Actinium Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. increased its stake in Actinium Pharmaceuticals by 82.0% in the 1st quarter. Rockefeller Capital Management L.P. now owns 6,881 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 3,101 shares during the period. Blair William & Co. IL acquired a new position in Actinium Pharmaceuticals in the 1st quarter valued at $265,000. Pinnacle Associates Ltd. acquired a new position in Actinium Pharmaceuticals in the 2nd quarter valued at $272,000. GSA Capital Partners LLP acquired a new position in Actinium Pharmaceuticals in the 1st quarter valued at $297,000. Finally, State Street Corp acquired a new position in shares of Actinium Pharmaceuticals during the 2nd quarter worth $437,000. Hedge funds and other institutional investors own 8.01% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2002 and is headquartered in New York, NY.

Featured Story: What Are Cryptocurrencies?

The Fly logo

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.